1. Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug‐drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling. Issue 1 (25th August 2021) Authors: Huth, Felix; Schiller, Hilmar; Jin, Yi; Poller, Birk; Schuhler, Carole; Weis, Wendy; Woessner, Ralph; Drollmann, Anton; End, Peter Journal: Clinical and translational science Issue: Volume 15:Issue 1(2022) Page Start: 118 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗